. RATIONALE: Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. Here we analyze dendritic cell (DC) populations in pediatric POIT subjects. METHODS: In a phase 1 single-center study, 15 subjects between 5-12 years with peanut allergy on POIT underwent immune evaluation at 0, 6, 12, 18 and 24-weeks after initiation of therapy and responders were compared to non-responders. The distribution frequency of plasmacytoid DCs (pDCs), myeloid DCs (mDCs) and tolerogenic DCs (DC10s) from peripheral blood samples were measured in vitro. One-way ANOVA was used for analysis. RESULTS: Non-responders to POIT demonstrated a higher frequency of inflammatory pDC IL-6 producing populations (Lin-HLADR+CD123+IL6+) (p50.047) and a lower frequency of tolerogenic DC10 populations (Lin-HLADR+CD11c+CD14+) (p50.004), compared to responders. POIT responders demonstrated a decline in OX40L expressing mDCs (Lin-HLADR+CD11c+OX40L+) (p50.0357). Overall non-responders demonstrated a larger decline in DC10s compared to responders (p50.0041). CONCLUSIONS: POIT responders have reduced OX40L expressing mDCs and increased DC10s, suggesting a shift away from Th2 polarization. In contrast, non-responders demonstrated an increase in proinflammatory pDCs producing IL-6, which may contribute to the inhibition of Treg mediated suppression. In conclusion, these findings suggest that dendritic cells could potentially serve as an early marker of desensitization in subjects undergoing POIT. (SLIT) immunotherapy studies at UNC between 2010-2017 were enrolled in a longitudinal observational study. Those demonstrating tolerance to > _300mg of peanut were instructed to incorporate dietary peanut. A Qualtrics survey was administered via telephone to assess patient/parental perceptions of safety and lifestyle. RESULTS: 55 patients (median 2.9 yrs (1.2mo-7.5yrs) post-study completion) completed the survey. 89% reported continued peanut ingestion. 98% of parents ''definitely'' or ''probably'' felt their child was safer. 92.8% and 94.5% ''definitely'' or ''probably'' felt their child's quality of life and parental quality of life was improved, respectively. 87.3% consumed products labeled ''may contain peanut'', 92.7% felt more comfortable eating at restaurants, and 87.3% of parents were more comfortable with their children in unsupervised social settings. 50% of patients who discontinued peanut reported definite or probable improvement in all survey parameters. Notably, 65.5% reported allergies to other food(s). 85% carried epinephrine autoinjectors ''often'', and only 60% saw an allergist annually. CONCLUSIONS: Regular ingestion of peanut food after completion of food immunotherapy is associated with improved perceptions of safety and life satisfaction in patients and parents persisting years after study completion. Benefit was seen even in patients discontinuing peanut ingestion or also having allergies to other food(s). Unintended consequences may include increased risk-taking behavior, such as not carrying an Epipen or following up regularly with an allergist.
Dendritic Cell Frequencies are Early Markers of Desensitization in Peanut Oral Immunotherapy
Sara Anvari, MD, MSc, Levi Watkin, PhD, Victor Cardenas, BSc, Oluwatomi Hassan, BSc, and Carla M. Davis, MD FAAAAI; Baylor College of Medicine, Houston, TX. RATIONALE: Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. Here we analyze dendritic cell (DC) populations in pediatric POIT subjects. METHODS: In a phase 1 single-center study, 15 subjects between 5-12 years with peanut allergy on POIT underwent immune evaluation at 0, 6, 12, 18 and 24-weeks after initiation of therapy and responders were compared to non-responders. The distribution frequency of plasmacytoid DCs (pDCs), myeloid DCs (mDCs) and tolerogenic DCs (DC10s) from peripheral blood samples were measured in vitro. One-way ANOVA was used for analysis. RESULTS: Non-responders to POIT demonstrated a higher frequency of inflammatory pDC IL-6 producing populations (Lin-HLADR+CD123+IL6+) (p50.047) and a lower frequency of tolerogenic DC10 populations (Lin-HLADR+CD11c+CD14+) (p50.004), compared to responders. POIT responders demonstrated a decline in OX40L expressing mDCs (Lin-HLADR+CD11c+OX40L+) (p50.0357). Overall non-responders demonstrated a larger decline in DC10s compared to responders (p50.0041). CONCLUSIONS: POIT responders have reduced OX40L expressing mDCs and increased DC10s, suggesting a shift away from Th2 polarization. In contrast, non-responders demonstrated an increase in proinflammatory pDCs producing IL-6, which may contribute to the inhibition of Treg mediated suppression. In conclusion, these findings suggest that dendritic cells could potentially serve as an early marker of desensitization in subjects undergoing POIT. METHODS: Past participants in peanut oral (OIT) or sublingual (SLIT) immunotherapy studies at UNC between 2010-2017 were enrolled in a longitudinal observational study. Those demonstrating tolerance to > _300mg of peanut were instructed to incorporate dietary peanut. A Qualtrics survey was administered via telephone to assess patient/parental perceptions of safety and lifestyle. RESULTS: 55 patients (median 2.9 yrs (1.2mo-7.5yrs) post-study completion) completed the survey. 89% reported continued peanut ingestion. 98% of parents ''definitely'' or ''probably'' felt their child was safer. 92.8% and 94.5% ''definitely'' or ''probably'' felt their child's quality of life and parental quality of life was improved, respectively. 87.3% consumed products labeled ''may contain peanut'', 92.7% felt more comfortable eating at restaurants, and 87.3% of parents were more comfortable with their children in unsupervised social settings. 50% of patients who discontinued peanut reported definite or probable improvement in all survey parameters. Notably, 65.5% reported allergies to other food(s). 85% carried epinephrine autoinjectors ''often'', and only 60% saw an allergist annually. CONCLUSIONS: Regular ingestion of peanut food after completion of food immunotherapy is associated with improved perceptions of safety and life satisfaction in patients and parents persisting years after study completion. Benefit was seen even in patients discontinuing peanut ingestion or also having allergies to other food(s). Unintended consequences may include increased risk-taking behavior, such as not carrying an Epipen or following up regularly with an allergist.
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Component IgE and IgG4 levels in patients with natural tolerance or oral immunotherapy treatment Lucile Packard Children's Hospital, Stanford, CA. RATIONALE: Biomarkers of sustained unresponsiveness following oral immunotherapy (OIT) are actively being investigated. Unlike children desensitized through OIT, food-allergic children who develop natural tolerance (NT) do not usually require daily allergen ingestion to maintain tolerance. We sought to evaluate biologic differences between these populations, focusing on egg and milk. METHODS: We assessed whole and component IgE and IgG4 titers of milk (Bos d4, 5, 8) and egg (Gal d1,2,3) to individuals 36 weeks post-OIT regimen (n513 milk, 26 egg), and with NT (n520 milk, 30 egg). NT was defined as prior doctor diagnosed food allergy with history of reaction, followed by self-reported outgrowth. RESULTS: Patterns between egg and milk differed. The egg-NT cohort had significantly (FDR-adjusted P<0.01) more patients below the limit of detection for egg-specific or component IgE than children desensitized by OIT. While 45% of egg-NT children had detectible levels of IgE to at least one component, 56% of post-egg OIT children had detectable levels to all three components. For milk, only Bos-d8-specific IgE was significantly (FDR-adjusted P<0.01) lower in NT children than in those treated by OIT. No significant differences were detected in IgG4 levels between NT and post-OIT patients for either allergen. CONCLUSIONS: While changes in IgG4 are similar between groups, OIT does not appear to reduce component-IgE to comparable NT levels within the studied time frame. Further, these differences in IgE trends may be allergen specific. Understanding mechanistic differences between NT and OIT will provide insight for potential therapeutic targets and aid in directing post-OIT care.
